 |
|
Cancer immunotherapy shows long-term promise in lung cancer
April 25, 2008New, long-term results from a clinical trial presented today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association of the Study of Lung Cancer (IASLC) show that MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic), an immune-boosting treatment for lung cancer patients, reduces the risk of relapse after surgery -- to the same extent as chemotherapy but without the side-effects of chemotherapy.
Prof. Johan Vansteenkiste from University Hospital Gasthuisberg in Belgium described the results after 44-months follow-up from a double-blind, placebo-controlled trial in 182 patients with non-small-cell lung cancer -- the most common form of the disease.
After complete surgical resection of the tumor, patients were randomly assigned to receive either placebo injections or injections of MAGE-A3 ASCI administered over 27 months (five given at three-week intervals followed by eight given once every three months). MAGE-A3 is a tumor-specific antigen, expressed in 35-50% of non-small-cell lung cancer, but not on normal cells.
"The aim is to help the body immune system to recognize the MAGE-A3 antigen and therefore eliminate the cancer cells that express MAGE-A3," explains Prof. Vansteenkiste. "In other words, it is a kind of treatment method that makes the body immune system specifically attack the lung cancer cells."
After 44 months, 69 of 182 patients had experienced a recurrence of their cancer, including 57 deaths. Those given the MAGE-A3 injections had longer on average before their cancer recurred, were less likely to have any recurrence, and were less likely to die.
"Surgical resection is the standard treatment for patients with early stage lung cancer, but after complete resection about 50% will relapse and die from their cancer," says Prof. Vansteenkiste. "Postoperative chemotherapy is able to improve cure rates, but is sometimes poorly tolerated by patients recovering from thoracic surgery. In addition, not all patients are fit to receive chemotherapy. This is why the signal from this phase II randomized study is important: the reduction in risk of postoperative cancer relapse is similar to the one obtained with postoperative chemotherapy, while the side-effects of this new strategy are minimal compared to chemotherapy."
Most patients only experience mild reactions at the injection site and fever within 24 hours of the injection, he explained. "Therefore, it is suitable for long-term maintenance treatment and for most patients, including older patients or patients in weak physical condition after surgery, allowing them to live a normal life whilst on cancer treatment." A large Phase III trial of the therapy, named MAGRIT, is now underway.
European Society for Medical Oncology
"The aim is to help the body immune system to recognize the MAGE-A3 antigen and therefore eliminate the cancer cells that express MAGE-A3," explains Prof. Vansteenkiste. "In other words, it is a kind of treatment method that makes the body immune system specifically attack the lung cancer cells."
After 44 months, 69 of 182 patients had experienced a recurrence of their cancer, including 57 deaths. Those given the MAGE-A3 injections had longer on average before their cancer recurred, were less likely to have any recurrence, and were less likely to die.
"Surgical resection is the standard treatment for patients with early stage lung cancer, but after complete resection about 50% will relapse and die from their cancer," says Prof. Vansteenkiste. "Postoperative chemotherapy is able to improve cure rates, but is sometimes poorly tolerated by patients recovering from thoracic surgery. In addition, not all patients are fit to receive chemotherapy. This is why the signal from this phase II randomized study is important: the reduction in risk of postoperative cancer relapse is similar to the one obtained with postoperative chemotherapy, while the side-effects of this new strategy are minimal compared to chemotherapy."
Most patients only experience mild reactions at the injection site and fever within 24 hours of the injection, he explained. "Therefore, it is suitable for long-term maintenance treatment and for most patients, including older patients or patients in weak physical condition after surgery, allowing them to live a normal life whilst on cancer treatment." A large Phase III trial of the therapy, named MAGRIT, is now underway.
European Society for Medical Oncology
Lung Cancer News and Current Lung Cancer Events RSSAfrican-Americans have unique lung cancer risks from chronic obstructive pulmonary disease
Scientists at the M.D. Anderson Cancer Center have developed a risk prediction assessment for lung cancer specifically for African Americans that suggests a greater risk from chronic obstructive pulmonary disease (COPD).
Breaking the 'mucus barrier' with a new drug delivery system
Chemical engineers from Johns Hopkins University have broken the "mucus barrier," engineering the first drug-delivery particles capable of passing through human mucus - regarded by many as nearly impenetrable - and carrying medication that could treat a range of diseases. Those conditions include lung cancer, cervical cancer and cystic fibrosis, the research noted in a presentation scheduled for the 236th National Meeting of the American Chemical Society.
Newly detected air pollutant mimics damaging effects of cigarette smoke
A previously unrecognized group of air pollutants could have effects remarkably similar to harmful substances found in tobacco smoke, Louisiana scientists are reporting in a study scheduled for presentation today at the 236th National Meeting of the American Chemical Society.
Targeted radiation therapy can control limited cancer spread
Precisely targeted radiation therapy can eradicate all evidence of disease in selected patients with cancer that has spread to only a few sites, suggests the first published report from an ongoing clinical trial.
Experimental chemotherapy regimen shows promise in treating advanced lung cancer
A combination of chemotherapy agents that have been tested in other tumor types appears to be a promising alternative to standard treatment for advanced non-small cell lung cancer, according to a report in the August 15 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research.
If your first cigarette gave you a buzz and you now smoke, a gene may be to blame
Anyone who has ever tried smoking probably remembers that first cigarette vividly. For some, it brought a wave of nausea or a nasty coughing fit. For others, those first puffs also came with a rush of pleasure or "buzz."
Gene panel predicts lung cancer survival, study finds
Researchers from four leading cancer centers have confirmed that an analysis involving a panel of genes can be used to predict which lung cancer patients will have the worst survival. The finding could one day lead to a test that would help determine who needs more aggressive treatment.
Vitamin A pushes breast cancer to form blood vessel cells
Researchers at Georgetown University Medical Center have discovered that vitamin A, when applied to breast cancer cells, turns on genes that can push stem cells embedded in a tumor to morph into endothelial cells. These cells can then build blood vessels to link up to the body's blood supply, promoting further tumor growth.
Patients unaware of link between smoking and bladder cancer
Even though cigarette smoking accounts for up to half of all bladder cancer cases, few people are aware of the connection - including more than three-quarters of patients who have bladder cancer.
New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
The first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, shows promising anticancer results in mice, report researchers from Children's Hospital Boston.
More Lung Cancer News Articles
 | Lung Cancer: Myths, Facts, Choices--and Hope by Claudia I. Henschke, Peggy McCarthy, Sarah Wernick Winner of the 2003 American Society of Journalists and Authors' June Roth Memorial Award for Health and Medical Books. An authoritative book with new lifesaving strategies for those at risk and those already diagnosed. Lung cancer kills more women than breast cancer, more men than prostate cancer—because it's usually found too late. Claudia Henschke's groundbreaking research on early... |
 | How to Survive Lung Cancer - A Practical 12-Step Plan by Michael Lloyd Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer... |
 | 100 Questions & Answers About Lung Cancer (100 Questions & Answers about . . .) by Karen Parles, Joan H. Schiller This book deals with lung cancer from a doctor's perspective and a patient's... |
 | Surviving Cancer by Margie Levine When cancer specialists at Boston’s internationally renowned Dana-Farber Cancer Institute diagnosed Margie Levine with a deadly asbestos-related lung cancer, they predicted that she had only six months to live. Refusing to give up hope, she chose an approach that combined state-of-the-art medicine with her own holistic program. Eleven years later, her mind/body regimen has evolved into a... |
 | Voices of Lung Cancer: The Healing Companion: Stories for Courage, Comfort and Strength (Voices Of series) Provided by the patients, their friends, families, and caregivers of those diagnaosed with lung cancer, these very personal stories offer inspired insight into the ways families and professionals care for both themselves and the patient, gain a deeper understanding of the relationships, and learn to come to terms with the end of life. Included are essays by medical experts about the science of... |
 | What to Eat if You Have Cancer by Daniella Chace, Maureen Keane, John A. Lung Information on choosing the best foods to help combat the disease as well as the side effects of chemical, surgical, and radiation... |
 | Quick Facts on Lung Cancer (Quick Facts) by American Cancer Society Educate yourself about lung cancer What are your risk factors for lung cancer? Can you prevent it? How is lung cancer treated? What should you ask your doctor? QuickFACTS Lung Cancer is both a comprehensive and a quick read, with highlighted cover tabs for quick reference of specific topics. QuickFACTS Lung Cancer: Covers everything from risk factors to living well after cancer treatment ... |
| 100 Questions & Answers About Lung Cancer by Karen Parles, Joan H. Schiller | |
 | Lung Cancer: Making Sense of Diagnosis, Treatment, and Options by Lorraine Johnston Lung cancer is the number one cancer killer in the U.S., with over 170,000 new cases diagnosed each year. Despite this, it receives little attention from the media and little sympathy from the public. Those with lung cancer suffer more blame and stigma than other cancer patients, even though 50 percent of them are former smokers or have never smoked. Treatments for lung cancer can significantly... |
 | High-Resolution CT of the Lung by W. Richard Webb, Nestor L Müller, David P Naidich The thoroughly revised Third Edition of this widely acclaimed volume explains how to use the newest high-resolution CT technology to diagnose lung disease. Still the only text on the topic, this compact, affordable reference is written by the foremost experts in the field and provides cutting-edge technical and clinical information. This edition reviews new findings on expiratory scans and... |
| © 2008 BrightSurf.com |